Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRA | P10827 | 16/20 | 0.62 |
| ▸ | THRB | P10828 | 16/20 | 0.62 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.46 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | HTR2B | P41595 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6516914 | 0.93 | THRA (0.57) | THRATHRBMTNR1AMTNR1B | |
| SCHEMBL6515367 | 0.93 | THRB (0.57) | THRATHRBMTNR1AMTNR1B | |
| SCHEMBL6522292 | 0.91 | THRA (0.75) | THRATHRBMTNR1AMTNR1BHTR2A | |
| SCHEMBL6521709 | 0.90 | THRA (0.74) | THRATHRBKDM4E | |
| SCHEMBL6511090 | 0.89 | THRA (0.61) | THRATHRBMTNR1AMTNR1B | |
| SCHEMBL6854008 | 0.89 | THRB (0.61) | THRATHRBMTNR1AMTNR1B | |
| SCHEMBL6514122 | 0.89 | THRA (0.59) | THRATHRBMTNR1AMTNR1BHTR2A | |
| SCHEMBL6514295 | 0.86 | THRA (0.84) | THRATHRBMTNR1AMTNR1BHTR2A | |
| SCHEMBL6512178 | 0.84 | THRB (0.56) | THRATHRB | |
| SCHEMBL6515147 | 0.84 | THRA (0.68) | THRATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050032874-A1 | Anticholesterol agents; arteriosclerosis | BAYER AKTIENGESELLSCHAFT (DE) | 2005-02-10 | — | — | US | disclosed |
| US-6794406-B2 | FOR THERAPY AND PROPHYLAXIS OF ARTERIOSCLEROSIS AND HYPERCHOLESTEROLAEMIA | BAYER AKTIENGESELLSCHAFT (DE) | 2004-09-21 | — | — | US | disclosed |
| EP-1347959-A1 | INDOLE DERIVATIVES AS LIGANDS OF THYROID RECEPTORS | Bayer Aktiengesellschaft (DE) | 2003-10-01 | — | — | EP | disclosed |
| US-20030078288-A1 | Indole derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2003-04-24 | — | — | US | disclosed |
| WO-2002051805-A1 | INDOLE DERIVATIVES AS LIGANDS OF THYROID RECEPTORS | BAYER AKTIENGESELLSCHAFT (DE) | 2002-07-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078288-A1 | Indole derivatives | IDO1, IDO2, TPH2 | THRA 2460/4885THRB 1772/4885MTNR1A 26/4885 |
| US-20050032874-A1 | Anticholesterol agents; arteriosclerosis | HMGCR, CYP46A1, EBP | THRA 1917/4885THRB 1835/4885MTNR1A 348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.